220 related articles for article (PubMed ID: 15221819)
1. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
[TBL] [Abstract][Full Text] [Related]
2. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
[TBL] [Abstract][Full Text] [Related]
3. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
Preda A; Novikov V; Möglich M; Turetschek K; Shames DM; Brasch RC; Cavagna FM; Roberts TP
J Magn Reson Imaging; 2004 Nov; 20(5):865-73. PubMed ID: 15503324
[TBL] [Abstract][Full Text] [Related]
4. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
Fournier LS; Novikov V; Lucidi V; Fu Y; Miller T; Floyd E; Shames DM; Brasch RC
Radiology; 2007 Apr; 243(1):105-11. PubMed ID: 17329684
[TBL] [Abstract][Full Text] [Related]
5. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.
Gossmann A; Helbich TH; Mesiano S; Shames DM; Wendland MF; Roberts TP; Ferrara N; Jaffe RB; Brasch RC
Am J Obstet Gynecol; 2000 Oct; 183(4):956-63. PubMed ID: 11035346
[TBL] [Abstract][Full Text] [Related]
7. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
Turetschek K; Preda A; Floyd E; Shames DM; Novikov V; Roberts TP; Wood JM; Fu Y; Carter WO; Brasch RC
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):448-55. PubMed ID: 12722742
[TBL] [Abstract][Full Text] [Related]
8. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights.
Cheng HL; Wallis C; Shou Z; Farhat WA
J Magn Reson Imaging; 2007 Jan; 25(1):137-45. PubMed ID: 17139634
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations.
Raatschen HJ; Fu Y; Shames DM; Wendland MF; Brasch RC
Invest Radiol; 2006 Dec; 41(12):860-7. PubMed ID: 17099424
[TBL] [Abstract][Full Text] [Related]
10. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice.
de Lussanet QG; Beets-Tan RG; Backes WH; van der Schaft DW; van Engelshoven JM; Mayo KH; Griffioen AW
Eur J Cancer; 2004 May; 40(8):1262-8. PubMed ID: 15110892
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.
Reichert F; Barak V; Tarshis M; Prindull G; Tarshis E; Ben-Ishay Z
Eur J Haematol; 2005 Jul; 75(1):41-6. PubMed ID: 15946309
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
14. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
[TBL] [Abstract][Full Text] [Related]
15. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis.
Zhang XM; Yu D; Zhang HL; Dai Y; Bi D; Liu Z; Prince MR; Li C
J Magn Reson Imaging; 2008 Jun; 27(6):1309-16. PubMed ID: 18504761
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
Li KL; Wilmes LJ; Henry RG; Pallavicini MG; Park JW; Hu-Lowe DD; McShane TM; Shalinsky DR; Fu YJ; Brasch RC; Hylton NM
J Magn Reson Imaging; 2005 Oct; 22(4):511-9. PubMed ID: 16161072
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer.
de Lussanet QG; Backes WH; Griffioen AW; Padhani AR; Baeten CI; van Baardwijk A; Lambin P; Beets GL; van Engelshoven JM; Beets-Tan RG
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1309-15. PubMed ID: 16125874
[TBL] [Abstract][Full Text] [Related]
18. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer.
Su MY; Cheung YC; Fruehauf JP; Yu H; Nalcioglu O; Mechetner E; Kyshtoobayeva A; Chen SC; Hsueh S; McLaren CE; Wan YL
J Magn Reson Imaging; 2003 Oct; 18(4):467-77. PubMed ID: 14508784
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.
Padhani AR
J Magn Reson Imaging; 2002 Oct; 16(4):407-22. PubMed ID: 12353256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
